非布司他联合非诺贝特治疗痛风患者的临床疗效及对炎症因子的影响

Clinical Efficacy of Febuxostat Combined with Fenofibrate in the Treat⁃ment of Gout Patients and Its Effect on Inflammatory Factors

目的 探讨非布司他联合非诺贝特治疗痛风患者的临床疗效及对炎症因子的影响。方法 选取2021年6月—2022年5月茂名市中医院收治的90例痛风患者为研究对象,以随机数表法分为低剂量研究组、高剂量研究组及对照组,每组30例。对照组采用40 mg/d非布司他治疗,低剂量研究组采用40 mg/d非布司他+非诺贝特治疗,高剂量研究组采用80 mg/d非布司他+非诺贝特治疗,对比3组的血尿酸水平、血尿酸达标率、视觉模拟量表评分、C-反应蛋白、血沉、不良反应及血清炎症指标水平。结果 治疗1、3、6个月,高剂量研究组、低剂量研究组的血尿酸、血沉水平均优于对照组,且高剂量研究组优于低剂量研究组,差异有统计学意义(P<0.05)。3组患者的不良反应发生率均为10.00%,差异无统计学意义(χ^(2)=0.000,P>0.05)。3组的IL-6、TNF-α水平随着治疗时间的延长而下降,且在治疗6个月后,高剂量研究组、低剂量研究组的IL-6、TNF-α水平均低于对照组,且高剂量研究组低于低剂量研究组,差异有统计学意义(P<0.05)。结论 在痛风的治疗过程中,非布司他联合非诺贝特有一定的优越性和发展潜力,且高剂量非布司他疗效显著,是一种高效的治疗方法。

Objective To investigate the clinical efficacy of febuxostat combined with fenofibrate in the treatment of gout patients and its effect on inflammatory factors.Methods 90 gout patients admitted to Maoming Hospital of Tradi‐tional Chinese Medicine from June 2021 to May 2022 were selected as the research objects.They were divided into low-dose study group,high-dose study group and control group by random number table method,with 30 cases in each group.The control group was treated with 40 mg/d Febuxostat,the low-dose study group was treated with 40 mg/d Febuxostat+Fenofibrate,and the high-dose study group was treated with 80 mg/d Febuxostat+Fenofibrate.The blood uric acid level,blood uric acid compliance rate,visual analog scale score,C-reactive protein,erythrocyte sedimenta‐tion rate,adverse reactions,and serum inflammatory index levels of the three groups were compared.Results After treatment for 1 months,3 months,and 6 months,the blood uric acid and blood sediment levels in the high-dose and low-dose study groups were higher than those in the control group,and the high-dose study group was better than the low-dose study group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in all three groups of patients was 10.00%,the difference was not statistically significant(χ^(2)=0.000,P>0.05).The levels of IL-6 and TNF-αin 3 groups decreased with the prolongation of treatment time,and after 6 months of treatment,the levels of IL-6 and TNF-αin the high-dose and low-dose study groups decreased were all lower than the control group,and the high-dose study group was lower than the low-dose study group,the difference was statistically signifi‐cant(P<0.05).Conclusion In the treatment of gout,febuxostat combined with fenofibrate has certain advantages and development potential,and high dose febuxostat has remarkable curative effect,which is an efficient treatment method.